Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Carl L. Gordon, a director and significant stakeholder in MBX Biosciences , Inc. (NASDAQ:MBX), recently made substantial purchases of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Gordon acquired a total of 190,672 shares over several transactions on February 14 and February 18, 2025. The transactions were executed at prices ranging from $9.85 to $10.84 per share, amounting to a total investment of approximately $2,020,755. The timing appears opportune, as InvestingPro data shows the stock has rallied 20.8% in the past week, though it remains down 53.9% over six months.
These acquisitions were made indirectly, with shares held by entities associated with OrbiMed Advisors, where Gordon serves on the management committee. Following these transactions, Gordon’s total direct and indirect ownership in MBX Biosciences stands at over 3.25 million shares. With the company’s earnings report due on February 26, InvestingPro analysis reveals analyst price targets ranging from $30 to $44, suggesting significant potential upside. Subscribers can access 8 additional ProTips and comprehensive financial metrics through InvestingPro’s detailed research reports.
In other recent news, MicroBase Biosystems reported its first-quarter 2025 earnings, highlighting significant growth in its core business despite an overall revenue decline. The company’s revenue stood at $6 million, excluding $4.1 million in non-recurring milestone payments from the previous year. Gross margins expanded to 62% from 49% last year, and net earnings reached $856,000. MicroBase executed a share buyback of approximately 2.5 million shares, contributing to its financial strategies. The company also achieved IVDR accreditation for sales in the European Union, indicating compliance with stringent regulatory standards. Analysts have noted the company’s strategic positioning and growth potential, particularly in the Asian markets for antigens. MicroBase is targeting a 20-40% revenue growth and expects to maintain high gross margins in the high 50s for fiscal 2025. The company is focusing on expanding its recombinant antigen program, with an estimated annual spend of $500,000.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.